Integrin inhibitors and their methods of use

Details Integrin inhibitors and their methods of use Integrin inhibitors and their methods of use

2005-02-01

2005-02-01

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S314000, C514S318000, C514S333000, C514S341000, C514S342000, C514S343000, C514S422000, C514S424000, C544S331000, C544S332000, C546S175000, C546S194000, C546S256000, C546S270700, C546S274700, C546S278400, C548S314700, C548S526000, C548S527000, C548S547000, C548S550000

Reexamination Certificate

active

06849639

ABSTRACT:
The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as a αvβ3, αvβ5, αvβ6, α5β1and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

REFERENCES:
patent: 5721366 (1998-02-01), Abood et al.
patent: 5843906 (1998-12-01), Chandrakumar et al.
patent: 5849736 (1998-12-01), Wityak et al.
patent: 5952306 (1999-09-01), Hartman et al.
patent: 5952341 (1999-09-01), Duggan et al.
patent: 039 051 (1981-11-01), None
patent: WO 9708145 (1997-03-01), None
patent: WO 9735615 (1997-10-01), None
patent: WO 9736862 (1997-10-01), None
patent: WO 9818461 (1998-05-01), None
patent: WO 9930709 (1999-06-01), None
patent: WO 9930713 (1999-06-01), None
patent: WO 9931099 (1999-06-01), None
patent: WO 9932457 (1999-07-01), None
patent: WO 9933798 (1999-07-01), None
patent: WO 9937621 (1999-07-01), None
patent: WO 9950249 (1999-10-01), None
patent: WO 9958139 (1999-11-01), None
patent: WO 9967230 (1999-12-01), None
Douglas, Jr., Introduction to Viral Diseases, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1739-1747, 1996.*
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.*
Agrez et al. (1994), “The αvβ6 Integrin Promotes Proliferation of Colon Carcinoma Cells through a Unique Region of the β6 Cytoplasmic Domain”,J. Cell Biol.127:547-556.
Agrez et al. (1997), “Integrin αvβ6 Enhances Coxsackievisus B1 Lytic Infection of Human Colon Cancer Cells”,Virology,239:71-77.
Agrez et al. (1999), “The αvβ6 Integrin Induces Gelatinase B Secretion in Colon Cancer Cells”,Int. J. Cancer81:90-97.
Albericio et al. (1998), “Use of Onium Salt-Based Coupling Reagents in Peptide Synthesis”,J. Org. Chem.63:9678-9683.
Arner et al. (1995), “Signal Transduction Through Chondrocyte Integrin Receptors Induces Matrix Metalloproteinase Synthesis and Synergizes with Interleukin-1”,Arthritis&Rheumatism38(9):1304-1314.
Baati et al. (1999), “An Improved Method for the Preparation of Amidines via Thiophenylimidic Esters”,Synthesis6:927-929.
Beller et al., “Palladium-catalyzed Olefinations of Aryl Halides (Heck Reaction) and Related Transformations” inTransition Metals for Organic Synthesis(Wiley-VCH, Beller et al. (ed.) (1998)) pp. 208-240.
Berge et al. (1977), “Pharmaceutical Salts”,J. Pharm. Sci66(1):1-19.
Brooks (1997), “Integrin αvβ3: A Therapeutic Target”,Drug News Perspect.10(8):456-461.
Brooks et al. (1997), “Insulin-like Growth Factor Receptor Cooperates With Integrin αvβ5 to Promote Tumor Cell Dissemination In Vivo”,J. Clin. Invest.99(6): 1390-1398.
Bundgaard et al. (1989), “A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group”,J. Med. Chem.32(12):2503-2507.
Busk et al. (1992), “Characterization of Integrin αvβ6 as a Fibronectin-binding Protein”,J. Biol. Chem.267(9):5790-5796.
Carpino et al. (1999), “The Diisopropylcarbodiimide/1-Hydroxy-7-azabenzotriazole System: Segment Coupling and Stepwise Peptide Assembly”,Tetrahedron55:6813-6830.
Carreiras et al. (1999), “Migration Properties of the Human Ovarian Adenocarcinoma Cell Line IGROV1: Importance of αvβ3 Integrins and Vitronectin”,Int. J. Cancer80:285-294.
Carron et al. (1998), “A Peptidomimetic Antagonist of the Integrin αvβ3Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy”,Cancer Res.58:1930-1935.
Cheng et al. (1973), “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition I50) of an Enzymatic Reaction”,Biochem. Pharmacology22:3099-3108.
Cheresh (1991), “Structure, function and biological properties of integrin αvβ3on human melanoma cells”,Cancer and Metastasis Rev.10:3-10.
Clark et al. (1996), “Transient Functional Expression of αvβ3 on Vascular Cells during Wound Repair”,Am. J. Pathol.148(5):1407-1421.
Dunn, “Amidines and N-Substituted Amidines” inCompr. Org. Funct. Group Transform.vol. 5 (Pergamon (1995)) pp. 741-782 and 1161-1308.
Gautier et al., “Preparation and synthetic uses of amidines” inChem. Amidines ImidatesCh. 7 (Patai (ed), Wiley & Sons (1975)) pp. 283-348.
Gladson et al. (1997), “Vitronectin Expression in Differentiating Neuroblastic Tumors”,Am. J. Pathol.150(5):1631-1646.
Gonda (1990), “Aerosols for Delivery of Therapeutic and Diagnostic Agents to the Respiratory Tract”,Critical Review in Therapeutic Drug Carrier Systems6(4):273-313.
Haapasalmi et al. (1996), “Keratinocytes in Human Wounds Express αvβ6 Integrin”,J. Invest. Dermatol.106(1):42-48.
Hermann et al. (1999), “The Vitronectin Receptor and its Associated CD47 Molecule Mediates Proinflammatory Cytokine Synthesis in Human Monocytes by Interaction with Soluble CD23”,J. Cell Biol.144(4):767-775.
Horton (1997), “The αvβ3 Integrin Vitronectin Receptor”,Int. J. Biochem. Cell Biol.29(5):721-725.
Huang et al. (1996), “Inactivation of the Integrin β6 subunit Gene Reveals a Role of Epithelial Integrins in Regulating Inflammation in the Lungs and Skin”,J. Cell Biol.133(4):921-928.
Keenan et al. (1997), “Discovery of Potent Nonpeptide Vitronectin Receptor (αvβ3) Antagonists”,J. Med. Chem.,40(15):2289-2292.
Kim et al. (1994), “Vitronectin-driven Human Keratinocyte Locomotion Is Mediated by the αvβ5 Integrin Receptor”,J. Biol. Chem.269(43):26926-26932.
Marcinkiewicz et al. (1996), “One-Step Affinity Purification of Recombinant αvβ3Integrin from Transfected Cells”,Protein Expression and Purification8:68-74.
Maryanoff et al. (1989), “The Wittig Olefination Reaction and Modifications Involving Phosphoryl-Stabilized Carbanions. Stereochemistry, Mechanism, and Selected Synthetic Aspects”,Chem. Rev.89:863-927.
Munger et al. (1999), “The Integrin αvβ6 Binds and Activates Latent TGFβ1: A Mechanism for Regulating Pulmonary Inflammation and Fibrosis”,Cell96:319-328.
Natali et al. (1997), “Clinical Significance of αvβ3Integrin and Intercellular Adhesion Molecule-1 Expression in Cutaneous Malignant Melanoma Lesions”,Cancer Res.57:1554-1560.
Neff et al. (1998), “Foot-and-Mouth Disease Virus Virulent for Cattle Utilizes the Integrin αvβ3as Its Receptor”,J. Virol.72(5):3587-3594.
Nip et al. (1995), “The role of the integrin vitronectin receptor, αvβ3in melanoma metastasis”,Cancer and Metastasis Rev.14:241-252.
Niu et al. (1998), “Integrin-Mediated Signalling of Gelatinase B Secretion in Colon Cancer Cells”,Biochem. Biophys. Res. Commun.249:287-291.
Novák et al. (1999), “A Convenient Route to Cyanoguanidines”,Synth. Commun.29(10):1757-1766.
Panetti et al.(1993), “The αvβ5Integrin Receptor Regulates Receptor-mediated Endocytosis of Vitronectin”,J . Biol. Chem.268(16):11492-11495.
Passaniti et al. (1992), “Methods in Laboratory Investigation. A Simple, Quantitative Method for the Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor”,Lab. Invest.67(4):519-528.
Phillips et al. (1

Affiliated with

Also associated with

Rating

Integrin inhibitors and their methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Integrin inhibitors and their methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin inhibitors and their methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3446531